NCT03011320 - An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2017

Primary Completion Date

December 30, 2017

Study Completion Date

August 28, 2018

Conditions

Ovary Cancer

Interventions

DRUG

EC1456

intravenous (IV) bolus dose

DRUG

99mTc-Etarfolatide

Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) \[20 to 25 millicuries (mCi)\] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.

Trial Locations (2)

28025

Levine Cancer Institute-Concord/Clinical Trials, Concord

K1H 8L6

Ottawa Hospital, Ottawa